Tirzepatide: Revolutionary Drug in Management of “Diabesity”
##plugins.themes.academic_pro.article.main##
Abstract
Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Chouhan, V., Spal, S., & Kumar, R. (2022). Tirzepatide: Revolutionary Drug in Management of “Diabesity”. International Journal of Medical and Dental Sciences, 11(2), 2046–2050. https://doi.org/10.18311/ijmds/2022/636
References
- Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011; 60:3103-9. https://doi.org/10.2337/db11-0979 PMid:21984584 PMCid:PMC3219 957 DOI: https://doi.org/10.2337/db11-0979
- Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology. 1998; 139:4004-7. https://doi.org/10.1210/endo.139.9.6288 PMid:9724057 DOI: https://doi.org/10.1210/endo.139.9.6288
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18:3-14. https://doi.org/10.1016/j.molmet.2018.09.009 PMid:30473097 PMCid: PMC6308032 DOI: https://doi.org/10.1016/j.molmet.2018.09.009
- A study of Tirzepatide (LY3298176) in participants with type 2 diabetes not controlled with diet and exercise alone (SURPASS-1)- study results [Internet]. A study of tirzepatide (LY3298176) in participants with type 2 diabetes not controlled with diet and exercise alone- Study ResultsClinicalTrials.gov. [cited 2022 Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03954834
- A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes (SURPASS-2)- study results [Internet]. A study of tirzepatide (LY3298176) versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes- Study Results- ClinicalTrials.gov. [cited 2022 Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03987919?view=results
- A study of tirzepatide (LY3298176) versus insulin degludec in participants with type 2 diabetes (SURPASS-3)- study results [Internet]. A study of tirzepatide (LY3298176) versus insulin degludec in participants with type 2 diabetes - Study Results - ClinicalTrials.gov. [cited 2022 Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03882970?view=results
- A study of tirzepatide (LY3298176) once a week versus insulin glargine once a day in participants with type 2 diabetes and increased cardiovascular risk (SURPASS-4)study results [Internet]. A study of tirzepatide (LY3298176) once a week versus insulin glargine once a day in participants with type 2 diabetes and increased cardiovascular risk- Study Results - ClinicalTrials.gov. [cited 2022Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03730662?view=results
- A study of tirzepatide (LY3298176) versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin (SURPASS-5) study results [Internet]. A study of tirzepatide (LY3298176) versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin - Study Results - ClinicalTrials.gov. [cited 2022Jul11]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT04039503?view=results
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck
- MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022 Jun 4. https://doi.org/10.1056/NEJMoa2206038 PMid:35658024 DOI: https://doi.org/10.1056/NEJMoa2206038